Pan-Cancer Epigenetic Biomarker Selection from Blood Samples Using SAS
Clicks: 100
ID: 282813
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
29.7
/100
100 views
35 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #88 of 803 articles by views in arXiv
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 803 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A key focus in current cancer research is the discovery of cancer biomarkers
that allow earlier detection with high accuracy and lower costs for both
patients and hospitals. Blood samples have long been used as a health status
indicator, but DNA methylation signatures in blood have not been fully
appreciated in cancer research. Historically, analysis of cancer has been
conducted directly with the patient's tumor or related tissues. Such analyses
allow physicians to diagnose a patient's health and cancer status; however,
physicians must observe certain symptoms that prompt them to use biopsies or
imaging to verify the diagnosis. This is a post-hoc approach. Our study will
focus on epigenetic information for cancer detection, specifically information
about DNA methylation in human peripheral blood samples in cancer discordant
monozygotic twin-pairs. This information might be able to help us detect cancer
much earlier, before the first symptom appears. Several other types of
epigenetic data can also be used, but here we demonstrate the potential of
blood DNA methylation data as a biomarker for pan-cancer using SAS 9.3 and SAS
EM. We report that 55 methylation CpG sites measurable in blood samples can be
used as biomarkers for early cancer detection and classification.
| Reference Key |
yuan2018pancancer
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Xi Chen; Jin Xie; Qingcong Yuan |
| Journal | arXiv |
| Year | 2018 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.